EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism

Jiangxue Han, Shunwang Li, Weizhi Wang, Xinhai Jiang, Chao Liu, Lijuan Lei, Yining Li, Ren Sheng, Yuyan Zhang, Yexiang Wu, Jing Zhang, Yuhao Zhang und 2 weitere

Current Issues in Molecular Biology · 08.06.2023 · 45 (6) · 5052-5070

DOI: 10.3390/cimb45060321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 08.06.2023. Verfasst von Jiangxue Han und 13 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Biotechnology of Antibiotics, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chines…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences (CIFMS), Foundation National Natural Science Foundation of China, Chinese Pharmaceutical Association-Yiling Biomedical Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. Silencing information regulator 1 (SIRT1) was demonstrated to modulate cholesterol and lipid metabolism in NAFLD. Here, a novel SIRT1 activator, E1231, was studied for its potential improvement effects on NAFLD. C57BL/6J mice were fed a high-fat and high-cholesterol diet (HFHC) for 40 weeks to create a NAFLD mouse model, and E1231 was administered by oral gavage (50 mg/kg body weight, once/day) for 4 weeks. Liver-related plasma biochemistry parameter tests, Oil Red O staining, and hematoxylin-eosin staining results showed that E1231 treatment ameliorated plasma dyslipidemia, plasma marker levels of liver damage (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), liver total cholesterol (TC) and triglycerides (TG) contents, and obviously decreased hepatic steatosis score and NAFLD Activity Score (NAS) in the NAFLD mouse model. Western blot results showed that E1231 treatment significantly regulated lipid-metabolism-related protein expression. In particular, E1231 treatment increased SIRT1, PGC-1α, and p-AMPKα protein expression but decreased ACC and SCD-1 protein expression. Additionally, in vitro studies demonstrated that E1231 inhibited lipid accumulation and improved mitochondrial function in free-fatty-acid-challenged hepatocytes, and required SIRT1 activation. In conclusion, this study illustrated that the SIRT1 activator E1231 alleviated HFHC-induced NAFLD development and improved liver injury by regulating the SIRT1-AMPKα pathway, and might be a promising candidate compound for NAFLD treatment.

Schlagwörter

Stichwörter der Autor:innen

AMPKαE1231FFANAFLDSIRT1

Autor:innen und Institutionen

  • NHC Key Laboratory of Biotechnology of Antibiotics, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & P…

Förderung

  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • Foundation National Natural Science Foundation of China
  • Chinese Pharmaceutical Association-Yiling Biomedical Innovation Fund

Zitieren

APA

Han, J., Li, S., Wang, W., Jiang, X., Liu, C., Lei, L., Li, Y., Sheng, R., Zhang, Y., Wu, Y., Zhang, J., Zhang, Y., Xu, Y., & Si, S. (2023). SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism. Current Issues in Molecular Biology, 45(6), 5052-5070. https://doi.org/10.3390/cimb45060321

Vancouver

Han J, Li S, Wang W, Jiang X, Liu C, Lei L, et al. SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism. Current Issues in Molecular Biology. 2023;45(6):5052-5070. doi:10.3390/cimb45060321

BibTeX
@article{Han2023,
  author = {Han, Jiangxue and Li, Shunwang and Wang, Weizhi and Jiang, Xinhai and Liu, Chao and Lei, Lijuan and Li, Yining and Sheng, Ren and Zhang, Yuyan and Wu, Yexiang and Zhang, Jing and Zhang, Yuhao and Xu, Yanni and Si, Shuyi},
  title = {SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism},
  journal = {Current Issues in Molecular Biology},
  year = {2023},
  volume = {45},
  number = {6},
  pages = {5052--5070},
  doi = {10.3390/cimb45060321}
}
Kostenlos starten →